PharmaShots Weekly Snapshot (September 30–October 04, 2019)

1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B

Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis B

2. Janssen’s Niraparib Receives the US FDA’s Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer

Published: Oct 03, 2019 | Tags: Janssen, Niraparib, Receives, US, FDA, Breakthrough Therapy Designation, Metastatic Castration-Resistant Prostate Cancer

3. Silver Cloud Health Partners with Microsoft to Deploy AI for Enhancing its Digital Mental Healthcare

Published: Oct 02, 2019 | Tags: Silver Cloud Health, Partners, Microsoft, Deploy, AI, Digital Mental Healthcare

4. AstraZeneca’s Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA’s Approval for Severe Eosinophilic Asthma

Published: Oct 04, 2019 | Tags: AstraZeneca, Fasenra Pen, Pre-Filled Auto-Injector, Receives, US, FDA, Approval, Severe Eosinophilic Asthma

5.Gilead’s Descovy Receives the US FDA’s Approval for HIV Pre-Exposure Prophylaxis

Published: Oct 03, 2019 | Tags: Gilead, Descovy, Receives, US, FDA, Approval, HIV Pre-Exposure Prophylaxis

6. Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases

Published: Oct 03, 2019 | Tags: Takeda, Signs, License Agreement, Goldfinch Bio, GFB-024, Rare and Metabolic Kidney Diseases

7. Novo Nordisk Collaborates with Noom to Provide Digital Health Solutions Targeting Weight Management in Patients with Obesity

Published: Oct 01, 2019 | Tags: Novo Nordisk, Collaborates, Noom, Digital Health Solutions, Weight Management, Patients, Obesity

8. Eli Lilly Reports the Availability of Emgality (galcanezumab) to Prevent Migraine in Canada

Published:  Oct 02, 2019 | Tags: Eli Lilly, Reports, Availability, Emgality, galcanezumab, Prevent, Migraine, Canada

9. Merck’s Keytruda Receives NMPA’s Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in China

Published: Oct 02, 2019 | Tags: Merck, Keytruda, Receives, NMPA, Approval, Monotherapy, 1L, Advanced Non-Small Cell Lung Cancer, PD-L1 Tumor Expression, China

10. Eli Lilly Reports Results of Taltz (ixekizumab) in Head-to-Head P-IV IXORA-R Study for Moderate to Severe Plaque Psoriasis

Published: Oct 02, 2019 | Tags: Eli Lilly, Reports, Results, Taltz, ixekizumab, Head-to-Head, P-IV, IXORA-R, Study, Moderate to Severe Plaque Psoriasis

11. Philips Collaborates with Air Ambulance Kent Surrey Sussex to Provide Emergency Services in the UK

Published: Oct 03, 2019 | Tags: Philips, Collaborates, Air Ambulance Kent Surrey Sussex, Provide, Emergency Services, UK

12. Biocon and Mylan Launch Semglee (biosimilar, Insulin Glargine) in Australia

Published: Oct 03, 2019 | Tags: Biocon, Mylan, Launch, Semglee, biosimilar, Insulin Glargine, Australia

13. Novartis Signs a Multiyear Agreement with Microsoft to Transform Medicine with the Launch of AI Innovation Lab

Published: Oct 01, 2019 | Tags: Novartis, Signs, Multiyear Agreement, Microsoft, Reimagining Medicine, Launch, Novartis, AI Innovation Lab

14. Pfizer to Launch its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019

Published: Sept 30, 2019 | Tags: Pfizer, Launch, Zirabev, Biosimliar, Bevacizumab, US, 2019

15.Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

Published: Oct 01, 2019 | Tags: Eisai, Signs, Research, Option Agreement, Numab, Discover, Develop, Multi-Specific Antibody, Immunotherapies, Cancer

16. Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan

Published: Oct 01, 2019 | Tags: Taisho, Signs, Exclusive, License Agreement, Moberg Pharma, Develop, Commercialize, MOB-015, Japan

17. Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer

Published: Sept 30, 2019 | Tags: Roche, Reports, Result, Tecentriq, atezolizumab, P-III, IMvigor130 Study, Advanced Bladder Cancer

18.Janssen’s Invokana (canagliflozin) Receives the US FDA’s Approval for Patients with Type 2 Diabetes and Diabetic Kidney Disease

Published: Oct 01, 2019 | Tags: Janssen, Invokana, canagliflozin, Receives, US, FDA, Approval, Type 2 Diabetes, Diabetic Kidney Disease

19. AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

Published: Oct 01, 2019 | Tags: AstraZeneca, Divest, Worldwide, Commercialization, Rights, Losec, omeprazole, Cheplapharm

20. SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir

Published: Sept 30, 2019 | Tags: SymBio, Signs, Worldwide, Exclusive, License Agreement, Chimerix, Develop, Commercialize, Brincidofovir

21. Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

Published: Sept 30, 2019 | Tags: Celltrion, Co-Marketing Agreement, Juno, Australia

22. Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Published: Sept 30, 2019 | Tags: Vertex, Collaborates, Ribometrix, Discover, Develop, Three, RNA Targeted Candidates

23.Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP

Published: Sept 30, 2019 | Tags: Merck, Reports, Results, Recarbrio, imipenem, cilastatin, relebactam, P-III, RESTORE-IMI 2, HABP, VABP

24. GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

Published: Sept 30, 2019 | Tags: GSK, Reports, Results, Nucala, mepolizumab, REALITI-A, Severe Eosinophilic Asthma

25.Roche’s Rituxan (rituximab) Receives the US FDA’s Approval for Two Rare Blood Vessel Disorders in Pediatric Patients Aged 2yrs. and Above

Published: Sept 30, 2019 | Tags: Roche, Rituxan, rituximab, Receives, US, FDA, Approval, Two, Rare Blood Vessel Disorders, Pediatric Patients

26.Sobi to Acquire Dova Pharmaceuticals for $915M

Published: Sept 30, 2019 | Tags: Sobi, Acquire, Dova Pharmaceuticals, $915M

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on

Related post